Update to ACC/AHA HF Performance Measures; Quadruple Therapy and HF; ACEi, ARBs, and CKD
In this week’s View, Dr. Eagle looks at the 2024 update to the 2020 ACC/AHA Clinical Performance and Quality Measures for Adults With Heart Failure (HF). He then explores the eligibility and projected benefits of rapid initiation of quadruple therapy for newly diagnosed HF. Finally, Dr. Eagle discusses a systematic review of clinical trials investigating the use of angiotensin-converting enzyme inhibitors (ACEi) or angiotensin-receptor blockers (ARBs) for advanced chronic kidney disease (CKD).
X Links:
- Kim Eagle, MD, MACC keaglemd
Clinical Topics: Heart Failure and Cardiomyopathies, Acute Heart Failure, Cardiovascular Care Team, Prevention
Keywords: EaglesEyeView, Cardiac Amyloidosis, Heart Failure, Sodium-Glucose Transporter 2 Inhibitors, Heart Failure, Reduced Ejection Fraction, Prescription Drugs, Angiotensin-Converting Enzyme Inhibitors, Angiotensin Receptor Antagonists, Kidney Failure, Chronic
